Fundamental XR builds case for wider surgical simulation adoption

Tern plc

Fundamental XR is demonstrating how virtual surgical simulation can be integrated directly into medical training, with its work alongside Orbis International showing how the technology is being used before trainees move into live procedures.

At Korle Bu Teaching Hospital in Ghana, first-year resident Dr Patrick Sapana-Kosa completed more than 80 MSICS procedures and over 25 hours of virtual simulation before operating on a patient. The purpose is straightforward: trainees can practise repeatedly, make mistakes and correct them before those mistakes carry real clinical consequences.

The programme is already being used at scale within the hospital. Thirteen first-year residents have completed more than 230 hours of simulation training this year. The training is not optional. Residents begin with virtual simulation, then progress to wet labs and finally to live cases. Embedding simulation into the curriculum increases its practical relevance and reduces the risk that the platform is treated as an occasional training tool.

Residents can learn basic surgical steps in simulation before entering wet labs, allowing faculty to spend less time teaching fundamentals and more time on advanced guidance. Fundamental XR says the approach has also reduced errors during wet-lab sessions, which can help limit waste of tissue and surgical supplies.

The same model is being used at the Rwanda International Institute of Ophthalmology. Participants there have reported improvements in how they perform individual surgical steps after using the simulator.

Orbis now connects 22 partner institutions across Africa, Asia and South America through the programme. Hundreds of early-stage surgeons have used the technology and completed thousands of hours of virtual practice.

That reach gives Fundamental XR an opportunity to show that its platform can be deployed across different institutions rather than remaining tied to a single hospital or training environment. Broader use also gives the company more opportunities to demonstrate whether simulation can become a repeatable part of surgical education.

Tern plc (LON:TERN) backs exciting, high growth IoT innovators in Europe. They provide support and create a genuinely collaborative environment for talented, well-motivated teams.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Talking Medicines examines factors influencing prescribing decisions

Talking Medicines explains how healthcare professional conversations, clinical considerations and treatment perceptions can provide pharmaceutical companies with deeper insight into prescribing intent beyond traditional campaign metrics.

What HCPs say could reveal prescribing intent

Talking Medicines is using AI to analyse HCP conversations and identify the clinical and practical factors that may influence prescribing intent.

AI control of machines raises new security questions

AI is gaining the ability to control physical equipment, but establishing that machines are genuine, authorised and secure will be an important part of making this technology safe to deploy.

CAR-T therapy brings new approach to multiple myeloma treatment

CAR-T therapy is being used in multiple myeloma and is being studied earlier in the treatment pathway, with research focused on improving durability, safety and access.

Tern cuts H1 loss by 60% as portfolio growth and funding strengthen

Tern reduced its first-half loss by 60%, with net asset value improving and further fundraising strengthening the balance sheet. Additional funding has supported Talking Medicines and Device Authority, while continued progress across the portfolio provides further scope for value creation.

AI control of machines creates a new market for device trust

AI is beginning to control physical machines, increasing demand for technology that can verify device identity before those machines are allowed to act.

Search